Eli Lilly's weight-loss drug Zepbound and diabetes medication Mounjaro are no longer in short supply. That could limit ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro ... companies that make cheaper copies of tirzepatide will face new restrictions on marketing those medications.

Research shows patients taking weight-loss drugs like Ozempic and Wegovy are more likely to have food left in the stomach or ...

The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making ...

Metsera, a biotech focused on obesity treatments, came out of stealth only this year, and its lead drug is still in early ...

Now, research finds this scenario is more likely if the patient is taking popular new weight-loss meds such as Ozempic, Wegovy, Mounjaro or Zepbound ... medications might face a higher odds ...

The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug ...

The Medicine Foundry, which is expected to create 400 jobs, will be situated in the LEAP Research and Innovation District in ...